Skip to content

Author

José Pablo Miramontes González

We have 1 of 5 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Aug 2026

Lipoprotein(a): Cardiovascular Risk and Emerging Targeted Therapies.

Current evidence supports strong biological efficacy, but definitive proof of clinical benefit awaits ongoing randomized cardiovascular outcomes trials, including Lp(a)HORIZON (pelacarsen), OCEAN(a)-Outcomes (olpasiran) and ACCLAIM-Lp(a) (lepodisiran).

José Pablo Miramontes González · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.